佐力药业加码临床营养 核心优势赋能新增长

Core Viewpoint - Zhejiang Zuoli Pharmaceutical Co., Ltd. announced the acquisition of core assets related to multi-trace element injection solutions from Tibet Future Biopharmaceutical Co., Ltd. for 356 million yuan (including tax) [1] Group 1: Acquisition Details - The asset group includes already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)", along with relevant R&D and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [2] - The "Multi-trace Element Injection (I)" is the first exclusive pediatric-specific parenteral nutrition preparation in China, with very few companies holding the relevant approvals for such products, creating a natural high market barrier [2] Group 2: Company Performance - Zuoli Pharmaceutical has shown a strong growth trend, achieving a revenue of 2.28 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.48%, and a net profit attributable to shareholders of 510 million yuan, up 21.00% year-on-year [3] - The company has developed a product matrix centered around Wuling Capsules, with a focus on expanding into lower-tier markets and enhancing clinical value recognition through targeted marketing strategies [3] Group 3: Strategic Advantages - The company can leverage its market advantages in centralized procurement and essential drug products to synergize with the multi-trace element injection product group, meeting the growing diversified clinical needs [4] - This acquisition is expected to enhance the company's marketing capabilities and team potential, facilitating rapid market entry and deep penetration of the new products [4]